Cargando…

Plasma cell myeloma positive for t(14;20) with relapse in the central nervous system

t(14;20)(q32;q11)/IGH-MAFB is a rare chromosomal abnormality in plasma cell myeloma (PCM), accounting for 1-2% of PCM cases. Patients with this translocation may have a poor prognosis. However, the clinicopathological features and response to novel agents have not been well clarified. We present a 6...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murase, Takayuki, Inagaki, Atsushi, Masaki, Ayako, Fujii, Keiichiro, Narita, Tomoko, Ri, Masaki, Hanamura, Ichiro, Iida, Shinsuke, Inagaki, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	JSLRT 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798141/ https://www.ncbi.nlm.nih.gov/pubmed/31391406 http://dx.doi.org/10.3960/jslrt.19011

Ejemplares similares

Immunohistochemistry for identification of CCND1, NSD2, and MAF gene rearrangements in plasma cell myeloma
por: Murase, Takayuki, et al.
Publicado: (2019)

Ectopic Expression of MAFB Gene in Human Myeloma Cells Carrying (14;20)(q32;q11) Chromosomal Translocations
por: Hanamura, Ichiro, et al.
Publicado: (2001)

Immunohistochemistry for CCR4 C‐terminus predicts CCR4 mutations and mogamulizumab efficacy in adult T‐cell leukemia/lymphoma
por: Fujii, Keiichiro, et al.
Publicado: (2020)

Human T‐cell lymphotropic/leukemia virus type 1 (HTLV‐1) Tax‐specific T‐cell exhaustion in HTLV‐1‐infected individuals
por: Masaki, Ayako, et al.
Publicado: (2018)

P820: POTENTIAL IMMUNOSUPPRESSIVE EFFECT OF EXTRACELLULAR VESICLES FROM PATIENTS WITH MULTIPLE MYELOMA
por: Hagiwara, Shinya, et al.
Publicado: (2023)

Case report: Genomic analysis of a therapy-related chronic myelomonocytic leukemia with KMT2A rearrangement that progressed to acute myeloid leukemia with acute promyelocytic leukemia-like features
por: Suzuki, Tomotaka, et al.
Publicado: (2023)

Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma
por: Iida, Shinsuke, et al.
Publicado: (2018)

Clinical significance of tryptophan catabolism in Hodgkin lymphoma
por: Masaki, Ayako, et al.
Publicado: (2017)

Cyclin-dependent kinase 9 as a potential specific molecular target in NK-cell leukemia/lymphoma
por: Kinoshita, Shiori, et al.
Publicado: (2018)

Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma
por: Yoshida, Takashi, et al.
Publicado: (2018)

Potent anti-tumor activity of a syringolin analog in multiple myeloma: a dual inhibitor of proteasome activity targeting β2 and β5 subunits
por: Yoshida, Takashi, et al.
Publicado: (2018)

Achromobacter Infection Is Rare in Japanese Patients with Pulmonary B-cell Lymphoma
por: Aoyama, Satsuki, et al.
Publicado: (2017)

Hepatitis B virus reactivation in a myeloma patient with resolved infection who received daratumumab-containing salvage chemotherapy
por: Kikuchi, Takaki, et al.
Publicado: (2020)

t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs
por: Narita, T, et al.
Publicado: (2015)

Volunteer unrelated donor cell‐derived acute myeloid leukemia with RUNX1‐RUNX1T1
por: Hagiwara, Shinya, et al.
Publicado: (2021)

Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE‐1 (phase 2) Japanese cohort
por: Ri, Masaki, et al.
Publicado: (2022)

Multiple myeloma with central nervous system relapse
por: Egan, Philip A., et al.
Publicado: (2020)

Clinical significance of TP53 mutations in adult T‐cell leukemia/lymphoma
por: Sakamoto, Yuma, et al.
Publicado: (2021)

Multiple myeloma with high-risk cytogenetics and its treatment approach
por: Hanamura, Ichiro
Publicado: (2022)

Lower expression of activating transcription factors 3 and 4 correlates with shorter progression-free survival in multiple myeloma patients receiving bortezomib plus dexamethasone therapy
por: Narita, T, et al.
Publicado: (2015)

Serum lipidomics for exploring biomarkers of bortezomib therapy in patients with multiple myeloma
por: Maekawa, Keiko, et al.
Publicado: (2019)

Gain/Amplification of Chromosome Arm 1q21 in Multiple Myeloma
por: Hanamura, Ichiro
Publicado: (2021)

CCR7 alterations associated with inferior outcome of adult T‐cell leukemia/lymphoma under mogamulizumab treatment
por: Sakamoto, Yuma, et al.
Publicado: (2022)

Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (A.R.R.O.W.) and comparison with ENDEAVOR
por: Takezako, Naoki, et al.
Publicado: (2020)

Abstract: 14.20 Comparison Of The Basal View And A Previously Standardized Cleft Lip Rating Scale
por: Klein, Gabriel, et al.
Publicado: (2017)

TM-233, a novel analog of 1′-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities
por: Sagawa, Morihiko, et al.
Publicado: (2015)

A comprehensive evaluation of humoral immune response to second and third SARS-CoV-2 mRNA vaccination in patients with malignant lymphoma
por: Suzuki, Tomotaka, et al.
Publicado: (2023)

Humoral and cellular immune response to second and third severe acute respiratory syndrome coronavirus 2 mRNA vaccine in patients with plasma cell dyscrasia
por: Suzuki, Tomotaka, et al.
Publicado: (2023)

Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study
por: Sunami, Kazutaka, et al.
Publicado: (2020)

P929: CIRCULATING TUMOR DNA ASSESSMENT IMPROVES PROGNOSTIC PREDICTION IN RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING IXAZOMIB, LENALIDOMIDE, AND DEXAMETHASONE
por: Kogure, Yasunori, et al.
Publicado: (2023)

A Phase I/II Study for Dose-finding, and to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of NK012, an SN-38-Incorporating Macromolecular Polymeric Micelle, in Patients with Multiple Myeloma
por: Ri, Masaki, et al.
Publicado: (2017)

Spin, branching ratios and production characteristics of the $K^{*}$ (1420)
por: Basdevant, J L, et al.
Publicado: (1969)

Rare decay modes of K$^{%}$(1420) and K$^{%}$(892)
por: Jongejans, B, et al.
Publicado: (1978)

A measurement of K$^{*}$ (1420) decay branching ratios
por: Dehm, G, et al.
Publicado: (1974)

A Triangle Singularity as the Origin of the $a_1(1420)$
por: Alexeev, G.D., et al.
Publicado: (2020)

1420. Descriptive Epidemiology of UTI Hospitalizations in the US, 2018
por: Zilberberg, Marya, et al.
Publicado: (2021)

Current topics of functional links between primary cilia and cell cycle
por: Izawa, Ichiro, et al.
Publicado: (2015)

Mutation analysis of the EGFR pathway genes, EGFR, RAS, PIK3CA, BRAF, and AKT1, in salivary gland adenoid cystic carcinoma
por: Saida, Kosuke, et al.
Publicado: (2018)

Safety, pharmacokinetics, and efficacy of belantamab mafodotin monotherapy in Japanese patients with relapsed or refractory multiple myeloma: DREAMM-11
por: Iida, Shinsuke, et al.
Publicado: (2023)

Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells
por: WADA, NAOKO, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_fqocpk4b6i6bohud5g55u5h8dp